Enanta PharmaceuticalsENTA
Market Cap: $250M
About: Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Employees: 145
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
106% more call options, than puts
Call options by funds: $140K | Put options by funds: $68K
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
7% less funds holding
Funds holding: 106 [Q1] → 99 (-7) [Q2]
11.08% less ownership
Funds ownership: 115.01% [Q1] → 103.93% (-11.08%) [Q2]
25% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 44
33% less capital invested
Capital invested by funds: $425M [Q1] → $285M (-$140M) [Q2]
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
JP Morgan Eric Joseph 48% 1-year accuracy 12 / 25 met price target | 15%downside $10 | Underweight Maintained | 6 Aug 2024 |
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 141 met price target | 129%upside $27 | Buy Reiterated | 6 Aug 2024 |